The Melanocortin Pathway and MC1R
Skin pigmentation is governed in part by the melanocortin system. The hormone alpha-melanocyte-stimulating hormone (alpha-MSH) binds the melanocortin-1 receptor (MC1R) on melanocytes, triggering a cascade that shifts pigment production toward eumelanin, the darker pigment responsible for tanning and for photoprotection. There are five melanocortin receptors (MC1R through MC5R) distributed across different tissues, and which receptors a given molecule activates largely determines what it does.
Both Melanotan I and Melanotan II are synthetic analogs of alpha-MSH designed to be more potent and longer-lasting than the natural hormone, so that they can drive melanogenesis at low doses and with more UV-independent effect than sun exposure alone. The crucial difference between the two lies not in whether they hit MC1R, but in how many other melanocortin receptors they also engage.
Melanotan I / Afamelanotide: The Approved Molecule
Melanotan I is the common name for afamelanotide, chemically a modified alpha-MSH analog. It is relatively selective for MC1R, which means its primary action is the pigment-producing pathway with comparatively less activity at the other melanocortin receptors. That selectivity is part of why it became a legitimate drug rather than only a research chemical.
Afamelanotide is approved — marketed as Scenesse — for erythropoietic protoporphyria (EPP), a rare inherited disorder in which sunlight causes severe pain. It received FDA approval in 2019 and is delivered as a small subcutaneous implant that releases the peptide over time, increasing eumelanin to provide photoprotection. Its approval is narrow and specific to EPP; it is not approved as a cosmetic tanning agent, and the approved product is a clinician-administered implant, not a self-injected research vial.
Melanotan II: Broader Receptor Profile, No Approval
Melanotan II is a cyclic analog of alpha-MSH with a much broader receptor profile. In addition to MC1R (pigmentation), it activates MC3R, MC4R, and MC5R to varying degrees. This lack of selectivity is the defining feature of MT-II: it is a more promiscuous agonist, and its extra activity — especially at MC4R in the central nervous system — produces effects well beyond tanning.
MT-II is not approved anywhere for any use. It is sold as a research chemical and is the compound most associated with the unregulated tanning-injection market that regulators have repeatedly warned against. Because it is handled as a research material, it carries all of the sourcing and sterility uncertainties described elsewhere on this site, on top of its own pharmacology.
The Arousal Side Effect That Became PT-141
One of MT-II's most consistent off-target effects is sexual arousal, including spontaneous erections in males, driven by its activation of central MC4R. In early research this was noted as a side effect of a tanning compound, but it was striking enough to become a therapeutic lead in its own right. Appetite suppression, also MC4R-mediated, is another central effect frequently reported with MT-II.
That line of investigation produced PT-141, or bremelanotide — a melanocortin agonist derived from the MT-II scaffold and optimized toward the arousal pathway rather than pigmentation. Bremelanotide was subsequently approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. The tanning peptide's side effect became the basis for a separate approved drug — a clean illustration of how receptor selectivity shapes a molecule's destiny.
Documented Safety Concerns and Regulatory Status
The documented safety concerns for the tanning peptides — and for MT-II in particular — are the reason regulators treat the unlicensed products so warily.
- Nausea and flushing: among the most common acute effects, tied to melanocortin receptor activation.
- Spontaneous erections and appetite suppression: MC4R-mediated central effects, prominent with MT-II.
- Darkening and proliferation of moles: reports of existing nevi darkening and new nevi appearing, which can complicate melanoma surveillance.
- Uncharacterized long-term risk: as unapproved injectables from unregulated sources, MT-II products carry contamination and dosing risks on top of their pharmacology.